Literature DB >> 20171594

Genetic regulation of serum cytokines in systemic lupus erythematosus.

Silvia N Kariuki1, Timothy B Niewold.   

Abstract

Genetic association studies in systemic lupus erythematosus (SLE) have been extremely successful in recent years, identifying several loci associated with disease susceptibility. Much work remains to integrate these loci into the functional pathogenic pathways that characterize the disease. Our working hypothesis is that many genetic variations linked to SLE and autoimmunity mediate the risk of disease by altering cytokine profiles or responses to cytokine signaling. Genetic polymorphisms that affect cytokine signaling could alter thresholds for immune responses, resulting in proinflammatory presentation of self-antigens and the subsequent misdirection of adaptive immunity against self, which is observed in autoimmune disease. SLE is clinically heterogeneous and genetically complex, and we expect that individual genes and cytokine patterns will be more or less important to different disease manifestations and subgroups of patients. Defining these genotype-cytokine-phenotype relationships will increase our understanding of both initial disease pathogenesis as well as subsequent response/nonresponse to various therapies. In this review, we summarize some recent work in the area of SLE cytokine genetics and describe the implications for SLE, autoimmunity, and immune system homeostasis, which are revealed by these investigations. Copyright 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20171594      PMCID: PMC2827336          DOI: 10.1016/j.trsl.2009.08.012

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  69 in total

1.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

Review 2.  Systemic lupus erythematosus.

Authors:  Anisur Rahman; David A Isenberg
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

3.  Interferon alpha-induced lupus: proof of principle.

Authors:  Timothy B Niewold
Journal:  J Clin Rheumatol       Date:  2008-06       Impact factor: 3.517

Review 4.  Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease.

Authors:  Marta Scatena; Lucy Liaw; Cecilia M Giachelli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-23       Impact factor: 8.311

5.  Variant form of STAT4 is associated with primary Sjögren's syndrome.

Authors:  B D Korman; M I Alba; J M Le; I Alevizos; J A Smith; N P Nikolov; D L Kastner; E F Remmers; G G Illei
Journal:  Genes Immun       Date:  2008-02-14       Impact factor: 2.676

Review 6.  Type I interferon in systemic lupus erythematosus.

Authors:  M K Crow
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

7.  Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus.

Authors:  Timothy B Niewold; Tania L Rivera; Jill P Buyon; Mary K Crow
Journal:  Arthritis Rheum       Date:  2008-02

8.  Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction.

Authors:  Shizhong Han; Joel M Guthridge; Isaac T W Harley; Andrea L Sestak; Xana Kim-Howard; Kenneth M Kaufman; Bahram Namjou; Harshal Deshmukh; Gail Bruner; Luis R Espinoza; Gary S Gilkeson; John B Harley; Judith A James; Swapan K Nath
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

9.  Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus.

Authors:  Kimberly E Taylor; Elaine F Remmers; Annette T Lee; Ward A Ortmann; Robert M Plenge; Chao Tian; Sharon A Chung; Joanne Nititham; Geoffrey Hom; Amy H Kao; F Yesim Demirci; M Ilyas Kamboh; Michelle Petri; Susan Manzi; Daniel L Kastner; Michael F Seldin; Peter K Gregersen; Timothy W Behrens; Lindsey A Criswell
Journal:  PLoS Genet       Date:  2008-05-30       Impact factor: 5.917

Review 10.  The role of tumor necrosis factor-alpha in systemic lupus erythematosus.

Authors:  Martin Aringer; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2008-01-23       Impact factor: 5.156

View more
  42 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

2.  Interleukin-10 receptor expression and signalling were down-regulated in CD4⁺ T cells of lupus nephritis patients.

Authors:  H D Cui; Z M Qi; L L Yang; L Qi; N Zhang; X L Zhang; S Y Du; Y Jiang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

Review 3.  Interferons in autoimmune and inflammatory diseases: regulation and roles.

Authors:  Divaker Choubey; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

4.  The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes.

Authors:  Sandra Agik; Beverly S Franek; Akaash A Kumar; Marissa Kumabe; Tammy O Utset; Rachel A Mikolaitis; Meenakshi Jolly; Timothy B Niewold
Journal:  J Rheumatol       Date:  2011-11-01       Impact factor: 4.666

5.  Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

Authors:  Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold
Journal:  Arthritis Rheum       Date:  2011-04

6.  Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab.

Authors:  Peter Korsten; Nadera J Sweiss; Ulf Nagorsnik; Timothy B Niewold; Hermann-Josef Gröne; Oliver Gross; Gerhard A Müller
Journal:  Am J Kidney Dis       Date:  2010-10-25       Impact factor: 8.860

Review 7.  Interferon regulatory factors in human lupus pathogenesis.

Authors:  Rafah Salloum; Timothy B Niewold
Journal:  Transl Res       Date:  2011-02-08       Impact factor: 7.012

8.  Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus.

Authors:  Silvia N Kariuki; Beverly S Franek; Akaash A Kumar; Jasmine Arrington; Rachel A Mikolaitis; Tammy O Utset; Meenakshi Jolly; Mary K Crow; Andrew D Skol; Timothy B Niewold
Journal:  Arthritis Res Ther       Date:  2010-07-26       Impact factor: 5.156

9.  Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients.

Authors:  Silvia N Kariuki; Beverly S Franek; Rachel A Mikolaitis; Tammy O Utset; Meenakshi Jolly; Andrew D Skol; Timothy B Niewold
Journal:  J Biomed Biotechnol       Date:  2010-07-04

Review 10.  Immunogenetics of systemic lupus erythematosus: A comprehensive review.

Authors:  Yogita Ghodke-Puranik; Timothy B Niewold
Journal:  J Autoimmun       Date:  2015-08-29       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.